Harvard Bioscience Showcases Innovations in Preclinical Research
Harvard Bioscience, Inc. (NASDAQ: HBIO) is gearing up to showcase its cutting-edge product innovations at the Society of Toxicology (SOT) conference, a prominent event drawing attention from industry leaders and researchers alike. This much-anticipated event will take place in Orlando and is a significant platform for the company to reveal advancements that can potentially transform preclinical research and organoid therapeutic development.
SoHo™ Implantable Real-Time Telemetry Platform
Among the exciting new offerings is the SoHo telemetry platform. This state-of-the-art solution empowers researchers to efficiently collect and manage data from various small animal models, whether in shared housing or different range environments. Notably, the company will be introducing newly launched biopotential monitoring devices, which have broad applications across various studies, including neurotoxicity and cardiovascular toxicology, reinforcing its commitment to advancing health sciences.
Enhancing Data Management with GLP Compliance
The SoHo telemetry platform operates in conjunction with the GLP-compliant Ponemah data management system, streamlining the process of data collection, analysis, and reporting. This automation minimizes manual intervention, ensuring consistency in findings while also reducing operational costs and test cycle times. It is especially geared towards accommodating the latest trends in preclinical studies, including the integration of artificial intelligence for advanced data analysis.
VivaMARS™ Activity Monitoring System Presentation
In addition to its telemetry solutions, Harvard Bioscience plans to present the VivaMARS™ Activity Monitoring System at the conference. This powerful platform, fueled by Ponemah technology, provides GLP-compliant, real-time behavioral analysis vital for Contract Research Organizations (CROs) and pharmaceutical companies aiming to expedite their drug development processes.
Collaborative Presentation on Behavioral Monitoring
On the final day of the event, representatives from Harvard Bioscience will present a poster discussing insights garnered in collaboration with a leading CRO, the initial user of the VivaMARS technology. This presentation underscores the system's role in advancing neuropharmacology and neurotoxicology applications.
Introduction of Multi Channel Systems Mesh MEA™ Organoid Platform
Another highlight of the exhibition will be the innovative Mesh Microelectrode Array (MEA) platform, specifically designed for organoid applications. With this cutting-edge technology, researchers can achieve detailed, real-time electrophysiological measurements from live organoids, a critical advancement for safety pharmacology and toxicology studies.
Supporting Organoid Research Growth
Given the rising interest and application of organoids in research and therapeutic development, the Mesh MEA™ system stands out as a versatile tool that meets the needs of modern scientific inquiry. This system builds on Harvard Bioscience's significant expertise in in vitro MEA technology, facilitating a deeper understanding of organoid behavior and functionality.
Driving New Therapies Development
Jim Green, Chairman and CEO of Harvard Bioscience, expressed enthusiasm about their participation in the event, stating, "We are thrilled to showcase our latest breakthroughs at the SOT meeting. These innovations not only advance scientific inquiry but also aim to cut costs and shorten the time required to bring new drugs to market." Green also pointed out the increasing adoption of their Mesh MEA technology in long-term organoid studies, highlighting the National Institutes of Health's initiative to embrace this technology for furthering neuro organoid research.
Engagement at the Society of Toxicology Booth
During the Society of Toxicology meeting, visitors are encouraged to stop by Harvard Bioscience's booth (#1411) located at the Orange County Convention Center. The company representatives will be available to discuss their wide range of innovative solutions that support advancements in research and development.
About Harvard Bioscience
Harvard Bioscience, Inc. has established itself as a leader in developing and manufacturing technologies that support essential advancements in various life science applications, including pharmaceutical research and therapy discovery. Their diverse clientele ranges from highly regarded academic institutions to top-tier pharmaceutical and biotechnology firms, with operations spanning North America, Europe, and Asia. By blending direct and distribution channels, they ensure their cutting-edge products are accessible globally.
For additional details, please visit the official website of Harvard Bioscience for insights about their innovative solutions and products.
Frequently Asked Questions
What innovations are being showcased by Harvard Bioscience?
Harvard Bioscience is unveiling the SoHo telemetry platform, VivaMARS activity monitoring system, and Mesh MEA technology at the Society of Toxicology conference.
How does the SoHo telemetry platform benefit researchers?
This platform allows researchers to collect and analyze data effectively from multiple small animal models, improving efficiency and lowering operational costs.
What is the significance of the VivaMARS system?
The VivaMARS system provides real-time behavioral analysis and is particularly useful for CROs and pharmaceutical companies to accelerate drug development processes.
How does Mesh MEA support organoid research?
The Mesh MEA platform delivers real-time electrophysiological data from living organoids, enhancing research capabilities in pharmacology and toxicology.
Where can I find more information about Harvard Bioscience?
For more information, visit the official Harvard Bioscience website, where you can discover their full range of products and solutions.
